Filana Therapeutics (STU:PX91) Cyclically Adjusted Book per Share: €3.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PX91 Filana Therapeutics Inc STU:PX91
37 GF Score
Price €0.78
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Cyclically Adjusted Book per Share?

Filana Therapeutics STU:PX91 -4.29% 37 Cyclically Adjusted Book per Share is €3.00 as of Mar. 2026. GuruFocus rates STU:PX91 with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Filana Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €1.220. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Filana Therapeutics's average Cyclically Adjusted Book Growth Rate was -9.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -6.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -2.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Filana Therapeutics was 2.40% per year. The lowest was -23.20% per year. And the median was -7.50% per year.

As of today (2026-07-25), Filana Therapeutics's current stock price is €0.781. Filana Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €3.00. Filana Therapeutics's Cyclically Adjusted PB Ratio of today is 0.26.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Filana Therapeutics was 0.26. The lowest was 0.00. And the median was 0.00.


Filana Therapeutics  (STU:PX91) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Filana Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.781/3.00
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Filana Therapeutics was 0.26. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Filana Therapeutics Cyclically Adjusted Book per Share Related Terms


Filana Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics Cyclically Adjusted Book per Share Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.75 3.86 3.91 3.90 3.06

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.61 3.20 3.29 3.06 3.00

STU:PX91 vs BOLD, INKT, XLO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Filana Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Filana Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:PX91
37GF Score
Filana Therapeutics Inc STU:PX91
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Filana Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.22/330.2130*330.2130
=1.220

Current CPI (Mar. 2026) = 330.2130.

Filana Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.103 241.018 4.251
201609 2.746 241.428 3.756
201612 2.680 241.432 3.666
201703 2.372 243.801 3.213
201706 1.790 244.955 2.413
201709 1.446 246.819 1.935
201712 1.243 246.524 1.665
201803 1.211 249.554 1.602
201806 1.061 251.989 1.390
201809 0.994 252.439 1.300
201812 1.002 251.233 1.317
201903 0.954 254.202 1.239
201906 0.916 256.143 1.181
201909 0.920 256.759 1.183
201912 0.911 256.974 1.171
202003 0.909 258.115 1.163
202006 0.862 257.797 1.104
202009 0.796 260.280 1.010
202012 2.151 260.474 2.727
202103 5.904 264.877 7.360
202106 5.735 271.696 6.970
202109 5.683 274.310 6.841
202112 5.615 278.802 6.650
202203 5.378 287.504 6.177
202206 5.152 296.311 5.741
202209 5.010 296.808 5.574
202212 5.147 296.797 5.726
202303 4.564 301.836 4.993
202306 3.949 305.109 4.274
202309 3.450 307.789 3.701
202312 2.985 306.746 3.213
202403 1.672 312.332 1.768
202406 3.659 314.175 3.846
202409 3.130 315.301 3.278
202412 2.887 315.605 3.021
202503 2.444 319.799 2.524
202506 1.579 322.561 1.616
202509 1.439 324.800 1.463
202512 1.315 324.054 1.340
202603 1.220 330.213 1.220

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €3.00 mean?
Filana Therapeutics (STU:PX91) has a Cyclically Adjusted Book per Share of €3.00 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Filana Therapeutics and its competitors.
Is Filana Therapeutics' Cyclically Adjusted Book per Share too high?
Filana Therapeutics' current Cyclically Adjusted Book per Share is €3.00. Overall, Filana Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' Cyclically Adjusted Book per Share compare to BOLD and INKT?
Filana Therapeutics' Cyclically Adjusted Book per Share of €3.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Filana Therapeutics and its competitors. Filana Therapeutics's current Cyclically Adjusted Book per Share is €3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (STU:PX91) has a current Cyclically Adjusted Book per Share of €3.00. The current Cyclically Adjusted Book per Share is €3.00. Filana Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Filana Therapeutics (STU:PX91), the current Cyclically Adjusted Book per Share is €3.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
37GF Score

Get the complete analysis for STU:PX91

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.78
Price